

Press Release
New Delhi
August 12, 2008

For Immediate Release

Panacea Biotec bags Award (USD 34. 2 million) for Pentavalent Vaccine, EasyFive* from UNICEF

Close on heels of receiving WHO pre-qualification in July'08, vaccine major Panacea Biotec has received an Award Notification for supply of its Pentavalent vaccine- EasyFive, for years 2008 & 2009. The total value of the award is USD 34.2 million (around Rs. 143 crores). EasyFive is **world's first fully liquid** pentavalent vaccine introduced in India, which immunizes children against five dreadful diseases (DTwP+ Hep B+ Hib) of early childhood.

EasyFive is also **India's first fully liquid** pentavalent vaccine pre-qualified by WHO in July this year. With this achievement, Panacea Biotec becomes the **first company in India** to get this award from UNICEF for its fully liquid pentavalent vaccine. Pentavalent vaccines are used by UN agencies (UNICEF, PAHO etc.) to vaccinate & save precious lives of millions of children in the developing world. The Indian Government also has plans to include pentavalent vaccines in its Expanded Program of Immunization.

EasyFive offers a befitting solution to overcome complexity of childhood vaccination program. With the introduction of EasyFive, the vaccination rates are likely to be increased and will make parents more willing to let children get all the shots they need in one visit, rather than scheduling multiple appointments, thus avoiding late vaccinations.

“There is an urgent need to foster innovation for the developing countries as the world is inching closer to the goal of eradicating dreadful diseases, especially for the early childhood, by providing effective vaccines. Immunization can prevent a million deaths. We at Panacea Biotec are partners with agencies worldwide to accelerate and spearhead a wide spectrum of technological innovations to develop vaccines that meet the unique needs of low-resource countries. We take this opportunity to thank entire team in Panacea Biotec, investors, shareholders, customers, suppliers & partners who have supported us to move from strength to size in becoming a truly global innovative company from India.” said Mr. Rajesh Jain, JMD- Panacea Biotec, highlighting the achievement.



As available in

Developing countries would need a combination vaccine to the tune of around 300 million doses annually. The combined demand of all combination pediatric vaccines worldwide was valued at USD 600 million in 2005 and is estimated to grow up to USD 1.6 billion by 2012. Pentavalent vaccine market is estimated to cross a mark of USD1 billion out of which UN agencies are likely to procure this vaccine worth more than USD 350 million (around Rs. 1,500 crore) by 2009 itself. The WHO prequalification for EasyFive and the subsequent order for supply have made Panacea Biotec a **global leader** in this important market segment.

Panacea Biotec has been playing an important role in immunization through its novel and innovative, world's first fully liquid vaccine with brands such as, 'EasyFour' & 'EasyFive', for over 3 years. It has partnered with WHO & UNICEF with a mission of supporting the cause of maximizing coverage of vaccines under the Expanded Program on Immunization (EPI) for more than a decade. Panacea Biotec in the past too has been granted pre-qualification by WHO for its other two combination vaccines, EasyFour (DTP + Hib) and Ecovac (DTP + Hep B) also. The company is already a pre-qualified supplier of OPV and Hepatitis-B vaccines to UN agencies.

About Panacea Biotec

Panacea Biotec is one of India's leading research-based health management companies with established research, manufacturing and marketing capabilities. Panacea Biotec is the 2nd largest vaccine producer in India. Panacea Biotec has been ranked as the 3rd largest biotechnology company (ABLE Survey 2008) and is also amongst the top 50 pharmaceutical companies in India. The product portfolio of the Company includes highly innovative vaccines, biopharmaceuticals and prescription products in important therapeutic areas such as pain management, diabetes management, renal-disease management, anti-osteoporosis, anti-tubercular, gastro-intestinal care products. The company has collaborations and tie-ups with leading national and international research organizations and corporations. The company's state of the art manufacturing facilities for vaccines and pharmaceutical formulations comply with the US-FDA, UK-MHRA, SA-MCC and WHO-cGMP standards. The company has five research and development centers. It has around 2800 employees including over 280 highly skilled scientists. The company also has 24 product patents, valid in more than 60 countries worldwide.

* Easyfive (Pentavalent) vaccine is available in different markets with antigens used from different sources i.e. Easyfive in India uses Hib from Novartis Vaccines and is meant for use in Indian market only whereas Easyfive PQ by WHO uses Hib developed by Panacea Biotec.

For further details please contact:

Mr. Pradeep Kumar Jain
GM - Corporate Communications & Govt. Affairs
Mobile: 09313482886
Land Line: 011-41678000; Fax: 011-41679096
Email: pradeepjain@panaceabiotec.com
Website: www.panaceabiotec.com

Disclaimer

Except for the historical information contained herein, statements in this Release which contain words or phrases such as 'will', 'would', 'indicating', 'expected to' etc., and similar expressions or variations of such expressions may constitute 'forward-looking statements'. These forward-looking statements involve a number of risks, uncertainties and other factors that could cause actual results to differ materially from those suggested by the forward-looking statements. These risks and uncertainties include, but are not limited to our ability to successfully implement our strategy, future business plans, our growth and expansion in business, the impact of any acquisitions, our financial capabilities, technological implementation and changes, the actual growth in demand for our products and services, cash flow projections, our exposure to market risks as well as other general risks applicable to the business or industry. Panacea Biotec undertakes no obligation to update forward-looking statements to reflect events or circumstances after the date thereof.